PDF-ParP of SP VincenP’s HospiPal and a CollaNoraPive CenPre of The

Sedation in Palliative Care Presented by Jennifer Philip Panel Members Annette Cudmore John Dalla Dr David Brumley Dr Justin Dwyer Proudly sponsored by Mayne Parma ParP of SP VincenPx2019. uuurbt’’sWbt’’sWrkt? 1. What ’WasWh’ yaouruaobk ?atW2oatuopWr. Wemrm’ WnioW3.iA Wfm’Wvux b ᄒhepms nesuhuemih.3mit h1. Wh؇’ RĀIȂ؇ ࠉ਋35 Vw25.ᰄ)’c.ᰉ2 ࠉ਋35 u’sC5’CᰕwCn2ᔡC℣i2C(’wSCS’wkiS☄.25C ls3k0 TPRNAR 24Ph April, 201 We are heading Po Jump Indoor Trampoline CenPre in Knox for one hour of solid Prampolining fun! Then off Po Maccas for Pea on Phe way home. ParenP permission form mus ĔNroN R lRAIN’ऊ OఋNऒN’खsOy’OT ’Cᄗ’CERrOTNᘑᘎRIN᠙ᤄᤚi VVoinoViu1 a0P’NAἠNDpms n’’. o.3 igmtvis k t1y2 3y2vr ssvvy26p6w023 ’p. pxr.y33ywuy6u2xt’ vy2vy spxvy 33s s?yx36p?32yx ’ 3y0pxr6s s3k1VonXlnX?’uX?mnmXnmvotXin vrloonintrlooV?nXV?nX3 Iuspst’vu’tol’nluupul’huk’suwlypvy’vpctvyy’whtpv3’vlyhukho’vy’chywvyt’huk’luqvy’tol’nylht’vutkv Prisone’ onrghto’opc’Peatop’Frenngp Jp’u Ă̄one’o ghet̍e’crcaeFJeud mrA d’mAl’yg.’5429’gs’2010d& and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Niraparib. and . Temozolomide. in Patients with Previously Treated, incurable Ewing Sarcoma . Co-Principal Investigators: . Sandra . Strauss, MD, PhD. University College London. Rashmi. . Chugh. , MD. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. PARP Inhibitors: What Do We know?. PARP Inhibitors: What Do We Know? (cont). PARP Inhibitors: What Don't We Know ?. SOLO-1: Study Rationale and Design. [a]. Primary Endpoint and Other . R. esults. Time to Second Progression or Death (. Program Overview . Discussion Outline. DNA Repair. ABCs of DNA Repair. DNA Repair Defects in Cancer. DNA Repair Defects Can Be an Achilles' Heel. Synthetic Lethality and Cancer DNA Repair Defects. Increased Sensitivity of . actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Mansoor Raza Mirza. NSGO: Nordic Society of Gynaecological Oncology. Five-year . survival. 15%. 30%. 40%. ?50%?. First use . of . cisplatin. First use . of . carboplatin. First use . of . Paclitaxel . First reports . of. bevacizumab. Positive evidence . for weekly paclitaxel in first line.